日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) with heart and nerve symptoms: a plain language summary

一项关于他法米地治疗伴有心脏和神经症状的转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)患者的真实世界研究:简明语言摘要

Wixner, Jonas; Dispenzieri, Angela; Amass, Leslie; Carlsson, Martin; Riley, Steve; Powers, Evan; Kelly, Jeffery W

Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS

THAOS 研究分析了接受 Tafamidis 治疗的混合表型转甲状腺素蛋白淀粉样变性心肌病患者的生存情况:一项当代真实世界队列研究的结果。

Wixner, Jonas; Dispenzieri, Angela; Amass, Leslie; Carlsson, Martin; Riley, Steve; Powers, Evan; Kelly, Jeffery W

Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic Benefits

ATTR淀粉样变性转甲状腺素蛋白动力学稳定剂:机制和治疗获益的叙述性综述

Powers, Evan T; Amass, Leslie; Baylor, Lori; Fernández-Arias, Isabel; Riley, Steve; Kelly, Jeffery W

Understanding how long people with transthyretin amyloid cardiomyopathy (ATTR-CM) live when they take tafamidis as part of their regular healthcare: a plain language summary

了解服用他法米地(tafamidis)作为常规医疗保健的一部分,转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)患者的生存期:简明语言概述

Garcia-Pavia, Pablo; Kristen, Arnt V; Drachman, Brian; Carlsson, Martin; Amass, Leslie; Maurer, Mathew S

Structure-primed embedding on the transcription factor manifold enables transparent model architectures for gene regulatory network and latent activity inference

基于转录因子流形的结构预嵌入方法能够构建透明的基因调控网络模型架构,并推断其潜在活性。

Tjärnberg, Andreas; Beheler-Amass, Maggie; Jackson, Christopher A; Christiaen, Lionel A; Gresham, David; Bonneau, Richard

Area deprivation index, a marker of socioeconomic disadvantage, may predict severity of COVID-19 in patients and which families may experience worse symptoms of PTSD, anxiety, and depression post-ICU

地区贫困指数(衡量社会经济劣势的指标)可能预测新冠肺炎患者的病情严重程度,以及哪些家庭在患者出院后可能出现更严重的创伤后应激障碍、焦虑和抑郁症状。

Mayer, Megan; Althoff, Meghan; Csikesz, Nicholas; Yu, Stephanie; Cruse, Hope; Stapleton, Renee; Amass, Timothy

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy

高剂量他法米地对混合表型变异型转甲状腺素蛋白淀粉样变性心肌病神经系统疾病进展的真实世界疗效

Streicher, Nicholas; Amass, Leslie; Wang, Rong; Stephens, Jennifer M; LeMasters, Traci; Raina, Rutika; Merrill, Emma; Sheikh, Farooq H

Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey

来自转甲状腺素蛋白淀粉样变性结局调查的混合表型转甲状腺素蛋白淀粉样变性患者的临床和基因型特征及症状迁移

González-Moreno, Juan; Dispenzieri, Angela; Grogan, Martha; Coelho, Teresa; Tournev, Ivailo; Waddington-Cruz, Márcia; Wixner, Jonas; Diemberger, Igor; Garcia-Pavia, Pablo; Chapman, Doug; Gupta, Pritam; Glass, Oliver; Amass, Leslie

Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

来自转甲状腺素蛋白淀粉样变性结果调查 (THAOS) 的 F64L、I68L、I107V 和 S77Y ATTRv 基因型的表型特征

Gentile, Luca; Diemberger, Igor; Plante-Bordeneuve, Violaine; Mazzeo, Anna; Dori, Amir; Luigetti, Marco; Di Paolantonio, Andrea; Dispenzieri, Angela; Grogan, Martha; Waddington Cruz, Márcia; Adams, David; Inamo, Jocelyn; Kristen, Arnt V; Lino Cirami, Calogero; Chapman, Doug; Gupta, Pritam; Glass, Oliver; Amass, Leslie

Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS

野生型转甲状腺素蛋白淀粉样变性患者的年龄和性别差异:来自THAOS的启示

Mora-Ayestaran, Nerea; Dispenzieri, Angela; Kristen, Arnt V; Maurer, Mathew S; Diemberger, Igor; Drachman, Brian M; Grogan, Martha; Gupta, Pritam; Glass, Oliver; Amass, Leslie; Garcia-Pavia, Pablo